Standard induction with basiliximab versus no induction in low immunological risk kidney transplant recipients: study protocol for a randomized controlled trial.

ABSTRACT:

Background

Induction therapy with IL-2 receptor antagonist (IL2-RA) is recommended as a first-line agent in low immunological risk kidney transplant recipients. However, the role of IL2-RA in the setting of tacrolimus-based immunosuppression has not been fully investigated.

Aims

To compare different induction therapeutic strategies with 2 doses of basiliximab vs. no induction in low immunologic risk kidney transplant recipients as per KFSHRC protocol.

Methods

Prospective, randomized, double blind, non-inferiority, controlled clinical trial EXPECTED OUTCOMES: 1. Primary outcomes: Biopsy-proven acute rejection within first year following transplant 2.

Secondary outcomes

a. Patient and graft survival at 1 year b. eGFR at 6 months and at 12 months c. Emergence of d

SUBMITTER: Ajlan A 

PROVIDER: S-EPMC8223264 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature